Fig. 4From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in ColombiaScatterplot with 1 000 Monte Carlo simulations of the incremental costs and benefits of palivizumab vs. placebo in infants with CHD, Colombia, 2022Back to article page